Combined therapy of gastroesophageal reflux disease in comorbidity with functional dyspepsia
https://doi.org/10.31146/1682-8658-ecg-211-3-41-45
Abstract
It has been shown that in patients with GERD and functional dyspepsia, the use of proton pump inhibitors leads to a decrease in heartburn and pain behind the sternum. However, symptoms such as regurgitation, belching, feeling of early satiety and heaviness after eating were stopped ineffectively. The inclusion in the treatment complex of the prokinetic domperidone at a dose of 10 mg 3 times a day contributed to a more effective regression of symptoms of impaired motility of the esophagus and stomach.
About the Authors
M. M. Karimov
The Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
P. S. Zufarov
The Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
G. N. Sobirova
The Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
D. K. Karimova
The Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
S. S. Khairullaeva
The Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation
Russian Federation
Russian Federation
References
1. de Bortoli N., Martinucci I., Bellini M., Savarino E., Savarino V., Blandizzi C., Marchi S. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol. 2013 Sep 21;19(35):5787-97. doi: 10.3748/wjg.v19.i35.5787.
2. Domperidone IND Packet US Food and Drug Administration. 2018. 17 p. Available at: https: //www.fda.gov/downloads/drugs/development_approval_process/how_drugs_are_developed_and_approved/appro Access 05.05.2021.
3. Drossman D. Rome III: The functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates, Inc., 2006, pp. 369-418.
4. Keohane J., Quigley E. M. Functional dyspepsia and nonerosive reflux disease: clinical interactions and their implications. MedGenMed. 2007 Aug 8;9(3):31. PMID: 18092037
5. Ortiz A., Cooper C. J., Alvarez A., Gomez Y., Sarosiek I., McCallum R. W. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015 May;349(5):421-4. doi: 10.1097/MAJ.0000000000000439.
6. Parkman H.P., Jacobs M. R., Mishra A., Hurdle J. A., Sachdeva P., Gaughan J. P., Krynetskiy E. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011 Jan;56(1):115-24. doi: 10.1007/s10620-010-1472-2.
7. Schey R., Saadi M., Midani D., Roberts A. C., Parupalli R., Parkman H. P. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Dig Dis Sci. 2016 Dec;61(12):3545-3551. doi: 10.1007/s10620-016-4272-5.
8. Wolfe M.M., Lowe R. C. Investing in the Future of GERD. J. Clin. Gastroenterol. 2007;41(Supplement 2): S209-S216. doi: 10.1097/MCG.0b013e318032390f
9. Yuan Y., Hunt R. H.Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am. J. Gastroenterol. 2008;103 (suppl 1): S50-S51. doi: 10.14309/00000434-200809001-00128.
Review
For citations:
Karimov M.M., Zufarov P.S., Sobirova G.N., Karimova D.K., Khairullaeva S.S. Combined therapy of gastroesophageal reflux disease in comorbidity with functional dyspepsia. Experimental and Clinical Gastroenterology. 2023;(3):41-45. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-211-3-41-45
Views:
280
Email this article 